Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661400 · ClinicalTrials.gov registry record · Phase 1
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01661400 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 14 participants.
The verdict
NCT01661400, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether taking either of two low dose drugs that would prevent new blood vessels from growing after stem cell transplant is feasible, and what the side effects of taking each of these drugs after autologous transplant might be. The reason the investigators are looking at these drugs is because one of the things that allows tumors to grow quickly is their ability to stimulate the growth of new blood vessels. By suppressing the growth of new blood vessels after stem cell transplant, the investigators hope to prevent the tumors from coming back or continuing to grow.
Interventions
- DRUG Thalidomide
- DRUG Metronomic Cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-10-26 |
| Est. Completion | 2023-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01661400
The ClinicalTrials.gov registry entry for NCT01661400 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thalidomide is the first listed.
NCT01661400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01661400 about?
NCT01661400 is a clinical study titled "Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors". The purpose of this research study is to determine whether taking either of two low dose drugs that would prevent new blood vessels from growing after stem cell transplant is feasible, and what the side effects of taking each of these drugs after autologous transplant might be. The reason the invest...
What is the current status of trial NCT01661400?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-10-26. Estimated completion is 2023-12-27.
What interventions are being tested in trial NCT01661400?
The interventions under investigation include: Thalidomide (DRUG), Metronomic Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT01661400?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.